Skip to main content
SpringerLink
Log in

Long-Acting Antipsychotic Medication and the Outcome of Schizophrenia

  • Chapter
  • First Online:
Advances in Schizophrenia Research 2009

  • 1519 Accesses

Abstract

Long-acting injectable antipsychotic medication or depots are an important element in the treatment of schizophrenia. Before assessing the pros and cons of such treatment and determining whether it has a significant impact on outcome over and above oral medication, it may be useful to consider where the idea of depot injections came from. There is surely a history behind this idea though it appears that a full account of this has yet to be written.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adams, C.E., Fenton, M.K.P., Quraishi, S., & David, A.S. (2001) Systemic meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry 179: 290–299

    Article  CAS  PubMed  Google Scholar 

  • Appelbaum, P.S., Robbins, P.C., & Monahan, J. (2000). Violence and delusions: data from the MacArthur violence risk assessment study. American Journal of Psychiatry 157: 566–572

    Article  CAS  PubMed  Google Scholar 

  • Arango, C., Barba, A.C., Gonzalez-Salvador, T., & Ordonez, A.C. (1999). Violence in inpatients with schizophrenia: a prospective study. Schizophrenia Bulletin 25: 493–503

    CAS  PubMed  Google Scholar 

  • Arango, C., Bombin, I., Gonzalez-Salvador, T., Garcia-Cabeza, I., & Bobes, J. (2006). Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. European Psychiatry 21: 34–40

    Article  CAS  PubMed  Google Scholar 

  • Arseneault, L., Moffitt, T.E., Caspi, A., Taylor, P.J., & Silva, P.A. (2000). Mental disorders and violence in a total birth cohort: results from the Dunedin study. Archives of General Psychiatry 57: 979–986

    Article  CAS  PubMed  Google Scholar 

  • Barnes, T.R. & Curson, D.A. (1994). Long-term depot antipsychotics: a risk-benefit assessment. Drug Safety 10: 464–479

    Article  CAS  PubMed  Google Scholar 

  • Buckley, P.F., Bartell, J., Donenwirth, K., Lee, S., Torigoe, F., & Schulz, S. (1995). Violence and schizophrenia: clozapine as a specific anti-aggressive agent. Bulletin of the American Academy of Psychiatry and the Law 23: 607–611

    CAS  PubMed  Google Scholar 

  • Buckley, P.F., Hrouda, D.R., Friedman, L., Noffsinger, S.G., Resnick, P.J., & Camlin-Shingler, K. (2004). Insight and its relationship to violent behavior in patients with schizophrenia. American Journal of Psychiatry 161: 1712–1714

    Article  PubMed  Google Scholar 

  • Buckley, P.F., Ibrahim, Z.Y., Singer, B., Orr, B., Donenwirth, K., & Brar, P.S. (1997). Aggression and schizophrenia: efficacy of risperidone. Journal of the American Academy of Psychiatry and Law 25: 173–181

    CAS  Google Scholar 

  • Chue, P., Eerdekens, M., Augustyns, I., Lachaux, B., Molcan, P., Eriksson, L., Pretorius, H., & David, A.S. (2005). Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. European Neuropsychopharmacology 15: 111–117

    Article  CAS  PubMed  Google Scholar 

  • Davis, J.M., Matalon, L., Watanabe, M.D., & Blake, L. (1994). Depot antipsychotic drugs. Place in therapy. Drugs 47: 741–773

    Article  CAS  PubMed  Google Scholar 

  • Dencker, S.J. & Axelsson, R. (1996). Optimising the use of depot antipsychotics. CNS Drugs 6: 367–381

    Article  CAS  Google Scholar 

  • Fleischhacker, W.W., Eerdekens, M., Karcher, K., Remington, G., Llorca, P.-M., Chrzanowski, W., Martin, S., & Gefert, O. (2003). Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Journal of Clinical Psychiatry 64: 1250–1257

    Article  CAS  PubMed  Google Scholar 

  • Gerlach, J. (1995). Depot neuroleptics in relapse prevention: advantages and disadvantages. International Clinical Psychopharmacology 9(Suppl. 5): 17–20

    Article  PubMed  Google Scholar 

  • Glazer, W.M. & Kane, J.M. (1992). Depot neuroleptic therapy: an underutilized treatment option. Journal of Clinical Psychiatry 53: 426–433

    CAS  PubMed  Google Scholar 

  • Gray, R., Leese, M., Bindman, J., Becker, T., Burti, L., David, A., Gournay, K., Kikkert, M., Koeter, M., Puscher, B., Schene, A., Thornicroft, G., & Tansella, M. (2006). Adherence therapy for people with schizophrenia: European multicentre randomised controlled trial. British Journal of Psychiatry 189: 508–514

    Article  PubMed  Google Scholar 

  • Haider, I. (1968). A controlled trial of fluphenazine enanthate in hospitalized chronic schizophrenics. British Journal of Psychiatry 114: 837–841

    Article  CAS  PubMed  Google Scholar 

  • Healy, D. (2000). The birth of psychopharmacotherapy: explorations’ in a new world 1952–1968. In: The Psychopharmacologists III. Interviews by Dr David Healy. Arnold, London, pp. 1–53

    Google Scholar 

  • Heres, S., Hamann, J., Kissling, W., & Leucht, S. (2006). Attitudes of psychiatrists toward antipsychotic depot medication. Journal of Clinical Psychiatry 67: 1948–1953

    Article  PubMed  Google Scholar 

  • Heres, S., Schmitz, F.S., Leucht, S., & Pajonk, F.G. (2007). The attitude of patients towards antipsychotic depot treatment. International Clinical Psychopharmacology 22: 275–282

    Article  PubMed  Google Scholar 

  • Heysue, B.E., Levin, G.M., & Merrick, J.P. (1998). Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatric Services 49: 1232–1234

    Google Scholar 

  • Hicks, R. & Ovenstone, I.M.K. (1996). Fluphenazine enanthate in the maintenance treatment of schizophrenia. British Medical Journal 29th Oct, 1071

    Google Scholar 

  • Hirsch, S.R., Gaind, R., Rohde, P.D., Stevens, B.C., & Wing, J. (1973). Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo controlled trial. British Medical Journal i: 633 –637

    Article  Google Scholar 

  • Hodgins, S. (1992). Mental disorder, intellectual deficiency and crime: evidence from a Danish birth cohort. Archives of General Psychiatry 49: 476–483

    CAS  PubMed  Google Scholar 

  • Hodgins, S., Hiscoke, U., & Freese, R., (2003). The antecedents of aggressive behavior among men with schizophrenia: a prospective investigation of patients in community treatment. Behavioral Sciences and the Law 21: 523

    Article  PubMed  Google Scholar 

  • Hogarty, G.E, Schooler, N.R, Ulrich, R., Mussare, I., Ferro, P., & Herron, E. (1979). Fluphenazine and social therapy in the aftercare of schizophrenic patients. Archives of General Psychiatry 36: 1283–1294

    CAS  PubMed  Google Scholar 

  • Hosalli, P. & Davis, J.M. (2003). Depot risperidone for schizophrenia. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD004161. DOI: 10.1002/14651858.CD004161

    Google Scholar 

  • Ioannidis J.P.A., Haidich, A.B., & Lau, J. (2001). Any casualties in the clash of randomised and observational evidence? British Medical Journal 322: 879–880

    Article  CAS  PubMed  Google Scholar 

  • Jones, P.B., Barnes, T.R.E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K.P., Murray, R.M., Markwick, A., & Lewis, S.W. (2006). Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63: 1079–1087

    Article  CAS  PubMed  Google Scholar 

  • Junginger, J., Parks-Levy, J., & Mcguire, L. (1998). Delusions and Symptom-Consistent Violence. Psychiatric Services 49: 218–220

    CAS  PubMed  Google Scholar 

  • Kane, J.M., Aguglia, E., Altamura, A.C., Ayuso Gutierrez, J.L., Brunello, N., Fleischhacker, W.W., Gaebel, W., Gerlach, J., Guelfi, J.D., Kissling, W., Lapierre, Y.D., Lindstrom, E., Mendlewicz, J., Racagni, G., Carulla, L.S., & Schooler, N.R. (1998). Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology 8: 55–66

    Article  CAS  PubMed  Google Scholar 

  • Kane, J.M., Eerdekens, M., Lindenmayer, J.P., Keith, S.J., Lesem, M., & Karcher, K. (2003). Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry 160: 1125–1132

    Article  PubMed  Google Scholar 

  • Kinross-Wright, J., Vogt, A.H., & Charalampous, K.D. (2003). A new method of drug therapy. American Journal of Psychiatry 119: 779–780

    Google Scholar 

  • Kemp, R., Hayward, P., Applewhaite, G., Everitt, B., & David, A. (1996). Compliance therapy in psychotic patients: randomised controlled trial. British Medical Journal 312: 345–349

    CAS  PubMed  Google Scholar 

  • Kemp, R., Kirov, G., Everitt, B., Hayward, P., & David, A. (1998). Randomised controlled trial of compliance therapy. 18-month follow-up. British Journal of Psychiatry 172: 413–419

    Article  CAS  PubMed  Google Scholar 

  • Kissling, W. (1994). Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatrica Scandinavica Supplement 382: 16–24

    Article  CAS  Google Scholar 

  • Kissling, W. (1997). Compliance, quality management and standards in the treatment of schizophrenia. Neuropsychobiology 35: 70–72

    Article  CAS  PubMed  Google Scholar 

  • Lauriello, J., Lambert, T., Andersen, S., Lin, D., Taylor, C.C., & Mcdonnell, D. (2008). An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. Journal of Clinical Psychiatry 69: 790–799

    Article  CAS  PubMed  Google Scholar 

  • Leff, J.P. & Wing, J.K. (1971). Trial of maintenance therapy in schizophrenia. British Medical Journal 11: 599–604

    Article  Google Scholar 

  • Lieberman, J.A., Stroup, T.S., Mcevoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S.E., Davis, S.M., Davis, C.E., Lebowitz,B.D., Severe, J., & Hsiao, J.K. (2005). And the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353: 1209–1223

    Article  CAS  PubMed  Google Scholar 

  • Link, B.G., Stueve, A., & Phelan, J. (1998). Psychotic symptoms and violent behavior: probing the components of “threat/control-override” symptoms. Social Psychiatry and Epidemiology 33: 55–60

    Article  Google Scholar 

  • Nose, M., Barbui, C., Gray, R., & Tansella, M. (2003). Clinical interventions for treatment non-adherence in psychosis: meta-analysis. British Journal of Psychiatry 183:197–206

    Article  PubMed  Google Scholar 

  • O’Donnell, C., Donohoe, G., & Sharkey, L. et al. (2003). Compliance therapy: a randomised controlled trial in schizophrenia. British Medical Journal 327: 834–838

    Article  PubMed  Google Scholar 

  • Patel, M.X., Dezoysa, N., Bernadt, M., Bindman, J., & David, A.S. (2007). Voluntary out-patients and coercion: depot versus oral antipsychotics. Schizophrenia Bulletin 33: 452

    Google Scholar 

  • Patel, M.X., & David, A.S. (2005). David AS. Why aren’t depot antipsychotics prescribed more often and what can be done about it? Advances in Psychiatric Treatment 11: 203–211

    Google Scholar 

  • Patel, M.X., Dezoysa, N., Baker, D., & David, A.S. (2005). Depot antipsychotic medication and attitudes of community psychiatric nurses. Journal of Psychiatric and Mental Health Nursing 12: 237–244

    Article  CAS  PubMed  Google Scholar 

  • Patel, M.X., Dezoysa, N., Bernadt, M., & David, A.S. (2008). Patients’ perspectives on adherence to antipsychotic medication: depots versus tablets. Journal of Clinical Psychiatry 69: 1548–1556

    Article  PubMed  Google Scholar 

  • Patel, M.X., Dezoysa, N., Bernadt, M., & David, A.S. (2009) Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. Journal of Psychopharmacology 23(7), 789–796. (published online ahead of print 26 June 2008, doi: 10.1177/0269881108092124)

    Google Scholar 

  • Patel, M.X., Nikolaou, V., & David, A.S. (2003a). Psychiatrists’ attitudes to maintenance medication for patients with schizophrenia. Psychological Medicine 33: 83–89

    Google Scholar 

  • Patel, M.X., Nikolaou, V., & David, A.S. (2003b). Eliciting psychiatrists’ beliefs about side effects of typical and atypical antipsychotic drugs. International Journal of Psychiatry in Clinical Practice 7: 117–120

    Google Scholar 

  • Robinson, D., Woerner, M.G., Alvir, J.M. et al. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry 56: 241–7

    Article  CAS  PubMed  Google Scholar 

  • Schanda, H., Knecht, G., Schreinzer, D., Stompe, T., Ortwein-Swoboda, G., & Waldhoer, T. (2004). Homicide and major mental disorders: a 25-year study. Acta Psychiatrica Scandinavica 110: 98–107

    Article  CAS  PubMed  Google Scholar 

  • Shi, L., Ascher-Svanum, H., Zhu, B., Faries, D., Montgomery, W., & Marder, S.R. (2007). Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatric Services 58: 482–488

    Article  PubMed  Google Scholar 

  • Simpson, G.M. (1974). A brief history of depot neuroleptics. Journal of Clinical Psychiatry 45: 3–4

    Google Scholar 

  • Steinert, T., Sippach, T., & Gebhardt, R. (2000). How common is violence in schizophrenia despite neuroleptic treatment? Pharmacopsychiatry 33: 98–102

    Article  CAS  PubMed  Google Scholar 

  • Swanson, J.W., Swartz, M.S., Van Dorn, R.A., Elbogen, E.B., Wagner, H.R., Rosenheck, R.A., Stroup, T.S., Mcevoy, J.P., & Lieberman, J.A. (2006). A national study of violent behavior in persons with schizophrenia. Archives of General Psychiatry 63: 490–499

    Article  PubMed  Google Scholar 

  • Swanson, J.W., Swartz, M.S., Van Dorn, R.A., Volavka, J., Monahan, J., Stroup, T.S., Mcevoy, J.P., Wagner, H.R., Elbogen, E.B., & Lieberman, J.A. (2008). Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. British Journal of Psychiatry 193: 37–43

    Article  PubMed  Google Scholar 

  • Swartz, M.S., Swanson, J.W., Hiday, V.A., Borum, R., Wagner, H.R., & Burns, B.J., (1998a). Taking the wrong drugs: the role of substance abuse and medication noncompliance in violence among severely mentally ill individuals. Social Psychiatry and Epidemiology 33: S75–S80

    Google Scholar 

  • Swartz, M.S., Swanson, J.W., Hiday, V.A., Borum, R., Wagner, H.R., & Burns, B.J., (1998b).Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. American Journal Psychiatry 155: 226–231

    Google Scholar 

  • Swartz, M.S., Swanson, J.W., Wagner, H.R., Burns, B.J., & Hiday, V.A., (2001). Effects of involuntary outpatient commitment and depot antipsychotics on treatment adherence in persons with severe mental illness. Journal of Nervous and Mental Disease 189: 592

    Article  Google Scholar 

  • Tattan, T.M.G. & Creed, F.H. (2001). Negative symptoms of schizophrenia and compliance with medication. Schizophrenia Bulletin 27: 149–155

    CAS  PubMed  Google Scholar 

  • Taylor, D., Mir, S., Mace, S., & Hogman, G. (1999). Is Cost a Factor – II? A Survey of Psychiatrists and Health Authorities to Determine the Factors Influencing the Prescribing and Funding of Atypical Antipsychotics. London: National Schizophrenia Fellowship

    Google Scholar 

  • Teasdale, B., Silver, E., & Monahan, J. (2006). Gender, threat/control-override delusions and violence. Law and Human Behavior 30: 649–658

    Article  PubMed  Google Scholar 

  • Tiihonen, J., Walhbeck, K., Lonnqvist, J., Klaukka, T., Ioannidis, J.P.A., Volavka, J., & Haukka, J. (2006). Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. British Medical Journal 333: 224

    Article  PubMed  Google Scholar 

  • Valenstein, M., Copeland, L.A., Blow F.C., Mccarthy J.F., Zeber, J.E., Gillon, L., Bingham, C.R., & Stavanger, T. (2002). Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care 40:630–639

    Article  PubMed  Google Scholar 

  • Volavka, J. (1999). The effects of clozapine on aggression and substance abuse in schizophrenic patients. Journal of Clinical Psychiatry 60: 43–46

    CAS  PubMed  Google Scholar 

  • Walburn, J., Gray, R., Gournay, K., Quraishi, S., & David, A.S. (2001). A systematic review of patient and nurse attitudes to depot antipsychotic medication. British Journal of Psychiatry 179: 300–307

    Article  CAS  PubMed  Google Scholar 

  • Walsh, E., Buchanan, A., & Fahy, T., (2002). Violence and schizophrenia: examining the evidence. British Journal of Psychiatry 180: 490–495

    Article  PubMed  Google Scholar 

  • Weiden, P. & Glazer, W. (1997). Assessment and treatment selection for ‘revolving door’ inpatients with schizophrenia. The Psychiatric Quarterly 68: 377–392

    Article  CAS  PubMed  Google Scholar 

  • Zygmunt, A., Olfson, M., Boyer, C.A., & Mechanic, D. (2002). Interventions to improve medication adherence in schizophrenia. American Journal of Psychiatry 159: 1653–1664

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Cognitive Neuropsychiatry, Institute of Psychiatry, KCL, SE5 8AF, London, UK

    Anthony S. David, Ayana Gibbs & Maxine X. Patel

Authors
  1. Anthony S. David
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ayana Gibbs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maxine X. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony S. David .

Editor information

Editors and Affiliations

  1. Fac. Medicina, Universidade de São Paulo, Rua Ovídio Pires Campos 785, Sao Paulo, 05403-903, Brazil

    Wagner F. Gattaz

  2. Fac. Medicina, Universidade de São Paulo, Rua Ovídio Pires Campos 785, Sao Paulo, 05403-903, Brazil

    Geraldo Busatto

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

David, A.S., Gibbs, A., Patel, M.X. (2010). Long-Acting Antipsychotic Medication and the Outcome of Schizophrenia. In: Gattaz, W., Busatto, G. (eds) Advances in Schizophrenia Research 2009. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0913-8_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-0913-8_23

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-0912-1

  • Online ISBN: 978-1-4419-0913-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation